ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL lessened its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 1.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 24,892 shares of the medical instruments supplier’s stock after selling 449 shares during the quarter. Gamco Investors INC. ET AL’s holdings in ICU Medical were worth $3,862,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ICUI. Barclays PLC lifted its position in ICU Medical by 15.6% in the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock valued at $10,790,000 after acquiring an additional 8,010 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of ICU Medical by 24.6% during the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock worth $23,130,000 after purchasing an additional 25,031 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of ICU Medical by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock valued at $416,176,000 after purchasing an additional 17,805 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of ICU Medical in the 4th quarter valued at about $556,000. Finally, Geode Capital Management LLC grew its stake in ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after buying an additional 48,106 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ICUI. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday. Raymond James set a $97.00 price target on shares of ICU Medical in a research report on Wednesday, March 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ICU Medical has a consensus rating of “Buy” and a consensus price target of $168.67.

ICU Medical Price Performance

ICU Medical stock opened at $138.67 on Friday. The business has a 50 day simple moving average of $146.73 and a 200-day simple moving average of $160.03. ICU Medical, Inc. has a 12 month low of $93.36 and a 12 month high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The stock has a market capitalization of $3.40 billion, a PE ratio of -30.34 and a beta of 0.86.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.